Peter Thompson Sells 59,767 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Posted by Geri Gentry on May 13th, 2026

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Peter Thompson sold 59,767 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $44.58, for a total value of $2,664,412.86. Following the sale, the director directly owned 2,856,461 shares in the company, valued at $127,341,031.38. This trade represents a 2.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Performance

NASDAQ:SION opened at $40.94 on Wednesday. Sionna Therapeutics, Inc. has a fifty-two week low of $11.77 and a fifty-two week high of $48.44. The stock has a market capitalization of $1.85 billion, a P/E ratio of -20.99 and a beta of 1.35. The company’s 50-day simple moving average is $38.93 and its 200-day simple moving average is $39.48.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, research analysts forecast that Sionna Therapeutics, Inc. will post -2.32 EPS for the current year.

Trending Headlines about Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

Positive Sentiment: Sionna completed enrollment in the PreciSION CF Phase 2a trial for SION-719, keeping the program on schedule for summer 2026 data and reducing execution risk. Article Title
Positive Sentiment: The company reported approximately $289.9 million in cash and cash equivalents, which it expects will fund operations into 2028, easing financing concerns. Article Title
Neutral Sentiment: Management said topline data from SION-719 and SION-451 studies are still expected in summer 2026, keeping investors focused on future catalysts rather than immediate commercial results. Article Title
Negative Sentiment: First-quarter EPS missed expectations, adding pressure to the stock despite pipeline progress. Article Title
Negative Sentiment: Recent insider sales by director Peter A. Thompson and OrbiMed Advisors may also be weighing on sentiment, even though the transactions were disclosed as pre-arranged 10b5-1 trades. Article Title

Hedge Funds Weigh In On Sionna Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SION. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics in the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at about $31,000. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at $36,000. Balyasny Asset Management L.P. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at $58,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at $89,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on SION shares. Wedbush started coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research report on Monday, April 27th. Guggenheim boosted their target price on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday. Finally, Citizens Jmp initiated coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Check Out Our Latest Report on SION

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.